Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Flu Vaccines
Study data from Vanderbilt University update knowledge of flu vaccines
September 17th, 2008
New research, 'Immunogenicity, safety and consistency of new trivalent inactivated influenza vaccine,' is the subject of a report. "To augment the available influenza vaccine supply, a phase III study was conducted to evaluate the immunogenicity, safety, and consistency of a new trivalent inactivated influenza vaccine manufactured by CSL Limited. Healthy adults (ages 18-64) were randomized to receive either a single dose of TIV from multi-dose vials with thimerosal, TIV from pre-filled syringes without thimerosal, or placebo," scientists in the United States report. "Of the TIV recipients, 97.8% achieved a post-vaccination titer >or=40 against H1N1, 99.9% against...
Source: Vaccine Weekly (2008-09-17)
|
